Recent Updates
Recently added Catalysts
TLX Negative Sentiment

TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders

Key Takeaway: Bragar Eagel & Squire, P.C. is conducting an investigation on behalf of Telix Pharmaceuticals investors due to potential violations of federal securities laws. Specifically, the firm is examining a subpoena received by Telix from the U.S. Securities and Exchange Commission regarding its disclosures related to prostate cancer therapies. This news has resulted in a substantial decline in Telix's ADR price. The law firm invites affected investors to discuss their rights and options.
Price reaction · baseline $10.04 (2025-10-14 close) · hit after-hours · clean, no other TLX news in the window
day 0 close
+9.7%
day 1
+8.2%
day 3
+7.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • Telix is under investigation for potential violations of federal securities laws.
  • The company received a subpoena from the U.S. SEC regarding disclosures related to prostate cancer therapeutics.
  • Following the news of the investigation, Telix's ADR price dropped significantly.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Telix and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ:TLX) on behalf of Telix stockholders. Our investigation concerns whether Telix has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."
On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.
If you purchased or otherwise acquired Telix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What should I do if I lost money on Telix shares?

Contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire to discuss your legal options.

What is the issue regarding Telix Pharmaceuticals?

Telix is being investigated for potential violations of federal securities laws.

What caused the drop in Telix's stock price?

The stock price fell after Telix announced it received a subpoena from the SEC.

How can I participate in the investigation into Telix?

You can get involved by contacting Bragar Eagel & Squire via phone or email.

Is there a cost to discuss my Telix claims?

No, there is no cost or obligation to discuss potential claims with the firm.

Last updated: Oct 15, 2025